Half Year Results 

Oncimmune in global expansion

Oncimmune in global expansion

Cancer diagnostics specialistOncimmune (ONC) may be lossmaking, but we’re encouraged by its significant international expansion in recent months. Indeed, as the deal flow picks up, analysts at Bryan Garnier expect the group's first cash profits in the 2020 financial year.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now